BACM
BIIB icon

Blue Arrow Capital Management’s Biogen BIIB Stock Holding History

Blue Arrow Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,000
Closed -$1.7M – 164
2014
Q4 		$1.7M Buy
+5,000
New +$1.62M 0.19% 113

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Blue Arrow Capital Management's BIIB Position: Q3 2014 in Review

Blue Arrow Capital Management sold out of Biogen (BIIB) in Q3 2014, closing a stake of 7,310 shares — an estimated $2.31M sold.

Blue Arrow Capital Management first reported a position in BIIB in Q1 2014 and held it in 2 quarters. The position peaked at $2.31M in Q2 2014. 819 funds tracked by Wall St. Rank hold BIIB as of Q3 2014.

  • Blue Arrow Capital Management reported no remaining Biogen position as of Q3 2014 after selling out during the quarter.
  • Blue Arrow Capital Management sold 7,310 Biogen shares in Q3 2014, an estimated $2.31M.
  • Blue Arrow Capital Management first reported a position in Biogen in Q1 2014 and held it in 2 quarters.
  • Blue Arrow Capital Management's Biogen position peaked at $2.31M in Q2 2014.
  • 819 funds tracked by Wall St. Rank held Biogen as of Q3 2014.

Based on Blue Arrow Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.